Skip to main content
SpringerLink
Log in

Evolving Therapies for Prostatic Carcinoma, Encompassing Orchiectomy, Estrogens, and Estramustine

  • Chapter
Estrogens, Progestins, and Their Antagonists

Part of the book series: Hormones in Health and Disease ((HHD))

  • 172 Accesses

Abstract

As the population ages, prostate cancer will become an even more significant problem. In 1995, approximately 240,000 men will be found to have prostate cancer (Wingo et al, 1995). Because of the routine use of Prostatic Specific Antigen (PSA) screenings, the percentage of patients who already have metastatic disease when prostate cancer is detected is much lower than it was 10 to 15 years ago (Catalona et al, 1991; Brawer et al, 1992). However, the treatment methods being used for many of these patients will fail, and these men will subsequently develop metastatic disease. Currently, there is no curative treatment for metastatic prostate cancer; therefore, novel therapies for metastatic prostate cancer are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD (1993): Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer 71:2782–2790.

    Article  PubMed  CAS  Google Scholar 

  • Bland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD (1990): A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer 66(5 Suppl):1074–1079.

    Google Scholar 

  • Blackledge G (1993): Casodex—mechanisms of action and opportunities for usage. Cancer (12 Suppl) 72:3830–3833.

    Article  PubMed  CAS  Google Scholar 

  • Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH (1992): Screening for prostatic carcinoma with prostate specific antigen. J Urol 147:841–845.

    PubMed  CAS  Google Scholar 

  • Byar DP (1973): Proceedings: The Veterans Administration Cooperation Urological Research Group’s studies of cancer of the prostate. Cancer 32:1126–1130.

    Article  PubMed  CAS  Google Scholar 

  • Cassileth BR, Soloway MS, Vogelzang NJ, Schellhammer PS, Seidmon EJ, Hait HI, Kennealey GT (1989): Patients’ choice of treatment in stage D prostate cancer. Urology 33:57–62.

    Article  PubMed  CAS  Google Scholar 

  • Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL (1991): Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161.

    Article  PubMed  CAS  Google Scholar 

  • Coffey DS (1992): The molecular miology, endocrinology, and physiology of the prostate and seminal vesicles. In: Campbell’s Urology, Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr, eds. 6th ed, Vol 1. Philadelphia: W.B. Saunders, pp. 221–266.

    Google Scholar 

  • Crawford ED, Davis MA (1988): LHRH analogues in the treatment of prostate cancer. In: Endocrine Therapies in Breast and Prostate Cancer, Osborne, CK, ed. Boston: Kluwer Academic, pp. 22–34.

    Google Scholar 

  • Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989): A controlled trial of le-uprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424.

    Article  PubMed  CAS  Google Scholar 

  • Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F (1993): Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908–913.

    PubMed  CAS  Google Scholar 

  • Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994): Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861–2864.

    PubMed  CAS  Google Scholar 

  • Huggins C, Hodges CV (1941): Studies on prostatic cancer: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297.

    CAS  Google Scholar 

  • Iversen P, Rasmussen F, Klarskov P, Christensen IJ (1993): Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer 72(12 Suppl):3851–3854.

    Article  PubMed  CAS  Google Scholar 

  • Janknegt RA (1993): Total androgen blockade with the use of orchiectomy and nilutamide (anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group. Cancer 72(12 Suppl):3874–3877.

    Article  PubMed  CAS  Google Scholar 

  • Keuppens F, Whelan P, Carneiro de Moura JL, Newling D, Bono A, Denis L, Robinson M, Mahler C, Sylvester R, De Pauw M, Vermeylen K, Ongena P (1993): Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer—Genitourinary Group. Cancer 72(12 Suppl):3863–3869.

    Article  PubMed  CAS  Google Scholar 

  • Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr (1986): Intermittent endocrine therapy for advanced prostate cancer. Cancer 58:2546–2550.

    Article  PubMed  CAS  Google Scholar 

  • Korenman SG (1991): Principles of therapy with reproductive steroids. In: Current Therapy in Endocrinology and Metabolism, Bardin CW, ed. Philadelphia: B.C. Decker, pp. 504–506.

    Google Scholar 

  • Labrie F (1993): Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 72:3816–3827.

    Article  PubMed  CAS  Google Scholar 

  • Labrie F, Dupont A, Belanger A (1985): Complete androgen blockade for the treatment of prostate cancer. In: Important Advances in Oncology, DeVita VT Jr, Hellman S, Rosenberg SA, eds. Philadelphia: J.B. Lippincott, pp. 193–215.

    Google Scholar 

  • Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Fazekas AT, Raynaud JP, Husson JM (1982): New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5:267–272.

    PubMed  CAS  Google Scholar 

  • Labrie F, Luthy I, Veilleaux R, Simard J, Belanger A, Dupont A (1987): New concepts on the androgen sensitivity of prostate cancer. Prog Clin Biol Res 243A: 145–172.

    PubMed  CAS  Google Scholar 

  • Mahler C (1993): Is disease flare a problem? Cancer 72(12 Suppl):3799–3802.

    Article  PubMed  CAS  Google Scholar 

  • McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C (1992): Expression of the protooncogene bcl-2 in the prostate and its association with emergence of antigen independent prostate cancer. Cancer Res 52:6940–6944.

    PubMed  CAS  Google Scholar 

  • McLeod DG (1995): Hormonal therapy in the treatment of carcinoma of the prostate. Cancer 75:1914–1919.

    Article  Google Scholar 

  • McLeod DG, Benson RC Jr, Eisenberger MA, Crawford ED, Blumenstein BA, Spicer D, Spaulding JT (1993): The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer 72(12 Suppl):3870–3873.

    Article  PubMed  CAS  Google Scholar 

  • Pienta KJ, Redman BG, Hussain M, Esper PS, Flaherty LE (1995): Inhibition of prostate cancer growth by estramustine and etoposide. Cancer 75:1920–1926.

    Article  Google Scholar 

  • Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE (1994): Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of “hormone-refractory” prostate cancer. J Natl Cancer Inst 86:222–227.

    Article  PubMed  CAS  Google Scholar 

  • Schally AV, Kastin AJ, Coy DH (1976): Edward T. Tyler Prize Oration: LH-releasing hormone and its analogues: Recent basic and clinical investigations. Int J Fertil 21:1–30.

    PubMed  CAS  Google Scholar 

  • Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck RH, Isaacs WB, Walsh PC, Barrack ER (1994): Microsatellite mutation (CAG24®18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 198:74–80.

    Article  PubMed  CAS  Google Scholar 

  • Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T (1992): Estramustine and vinblastine: Use of prostate specific antigen as clinical trial end point for hormone refractory prostatic cancer. J Urol 147:931–934.

    PubMed  CAS  Google Scholar 

  • Sonino N (1987): The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317:812–818.

    Article  PubMed  CAS  Google Scholar 

  • Stamey TA, McNeal JE (1992): Adenocarcinoma of the prostate. In: Campbell’s Urology, Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr, eds. 6th ed, Vol. 2. Philadelphia: WB Saunders, pp. 1159–1221.

    Google Scholar 

  • Wingo PA, Tong T, Bolden S (1995): Cancer statistics, 1995. CA Cancer J Clin 45:8–30.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Harper Hospital, 4160 John R, Suite 1017, 48201, Detroit, MI, USA

    David P. Wood Jr.

Authors
  1. David P. Wood Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Kentucky Medical Center, 800 Rose Street, 40536-0084, Lexington, KY, USA

    Edward J. Pavlik

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Birkhäuser Boston

About this chapter

Cite this chapter

Wood, D.P. (1997). Evolving Therapies for Prostatic Carcinoma, Encompassing Orchiectomy, Estrogens, and Estramustine. In: Pavlik, E.J. (eds) Estrogens, Progestins, and Their Antagonists. Hormones in Health and Disease. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4096-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-4096-9_6

  • Publisher Name: Birkhäuser Boston

  • Print ISBN: 978-1-4612-8650-9

  • Online ISBN: 978-1-4612-4096-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation